Table 2. Correlation between clinicopathological characters and expressions of Galectin-3 and Galectin-9.

Character	n	Expression of Galectin-3		Median H-score (quartile)	P	Expression of Galectin-9		Median H-score (quartile)	P
		0–120	121–300			0–100	101–300
Gender
Male	195	157 (80.5%)	38 (19.5%)	0(0–80)	0.390	110 (56.4%)	85 (43.6%)	90(40–180)	0.984
Female	52	44 (84.6%)	8 (15.4%)	0(0–90)		28 (53.8%)	24 (46.2%)	90(30–180)
Age
≤55ys	127	100 (78.7%)	27 (21.3%)	0(0–120)	0.110	74 (58.3%)	53 (41.7%)	90(20–180)	0.643
>55ys	120	101 (84.2%)	19 (15.8%)	0(0–60)		64 (53.3%)	56 (46.7%)	90(60–180)
HBV/HCV
HBV positive	158	123 (77.8%)	35 (22.2%)	0(0–120)	0.052	90 (57.0%)	68 (43.0%)	90(30–180)	0.817
HCV positive	45	41 (91.1%)	4 (8.9%)	0(0–0)		25 (55.6%)	20 (44.4%)	90(40–180)
Negative	44	37 (84.1%)	7 (15.9%)	0(0–60)		23 (52.3%)	21 (47.7%)	90(40–180)
Number of tumor
Single	183	151 (82.5%)	32 (17.5%)	0(0–80)	0.061	99 (54.1%)	84 (45.9%)	90(50–180)	0.561
Multiple	64	50 (78.1%)	14 (21.9%)	7.5(0-112.5)		39 (60.9%)	25 (39.1%)	90(5–180)
Tumor size
≤5 cm	137	117 (85.4%)	20 (14.6%)	0(0–80)	0.334	99 (54.1%)	84 (45.9%)	90(60–180)	0.427
>5 cm	110	84 (74.6%)	26 (23.4%)	0(0–120)		39 (60.9%)	25 (39.1%)	90(0–180)
Differentiation
Poor	75	59 (78.7%)	16 (21.3%)	15(0–100)	0.016	49 (65.3%)	26 (37.4%)	80(0–180)	0.002
Moderate/well	172	142 (82.6%)	30 (17.4%)	0(0–75)		89 (51.7%)	83 (48.3%)	90(60–180)
Lymph-vascular invasion
No	138	117 (84.8%)	21 (15.2%)	0(0–60)	0.049	71 (51.4%)	67 (48.6%)	90(67.5-180)	0.012
Yes	109	84 (77.1%)	25 (22.8%)	0(0–110)		67 (61.5%)	42 (38.5%)	90(0–180)
Cirrhosis
No	99	72 (72.7%)	27 (27.3%)	0(0–150)	0.040	53 (53.5%)	46 (46.5%)	90(50–180)	0.560
Yes	148	129 (87.2%)	19 (17.8%)	0(0–60)		85 (57.4%)	63 (42.6%)	90(22.5-180)
AJCC clinical stage
I	109	95(87.2%)	14 (12.8%)	0(0–60)	0.242	55 (50.5%)	54 (49.5%)	100(70–180)	0.106
II	100	74 (74.0%)	26 (26.0%)	0(0–140)		61 (61.0%)	39 (39.0%)	90(20–180)
III	38	32 (84.2%)	6 (15.8%)	0(0–90)		22 (57.9%)	16 (42.1%)	85(0–180)